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Abstract
Background: The dilated cardiomyopathy (DCM) is one of the most 
important causes of cardiac insufficiency, leading to morbidity and 
mortality augment, due to therapeutic restriction. 
Objective: To search scientific evidences about the treatment of 
dilated cardiomyopathy with stem cells use. 
Results: The stem cells use in this pathology has shown benefits 
through human and animals experiments, verified through images 
and laboratorial exams. 
Conclusion: Even with positive results, this treatment requires deeper 
studies that can show consistent vantages of this therapy in humans. 
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The dilated cardiomyopathy is a structural cardiac alteration by car-
diomyocytes alteration, resulting in a cardiac contractility impair-
ment, and, consequently, in cardiac insufficiency [1]. Morschbacher 
et al., (2016) [2] highlighting Nagaya et al., (2015) [3], demonstrated 
that, besides the cardiomyocytes alteration, there is an augment 
in the fibroblast number, which is another mechanism of cardiac 
insufficiency development. Despite the advances in medical area, 
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the cardiac insufficiency continues to presents high 
morbidity and mortality taxes.
Haddad et al., (2015) [4], highlighting the con-
cepts of Hunt et al., 2009 [5], have observed that 
almost 50% of the patients with advanced cardiac 
insufficiency are submitted to cardiac transplant 
or to mechanic circulatory support, and the stem 
cells therapy is presented as a promise to these pa-
tients.  
The justification for this goal is that this thera-
py performs a cardiomyocytes repair, leading to an 
augment of growth factors and cytokines, which 
diminishes the local inflammation, mitigating the 
progression of dilated cardiomyopathy and the left 
ventricle remodeling [6]. 
In a recently published study performed in Stan-
ford University, 37 patients with long-term dilated 
cardiomyopathy, from January 3 of 2011 to March 
5 of 2012, left ventricular ejection fraction (LVEF) < 
40% and Classification in New York Heart Associa-
tion (NYHA) III, were submitted to intramyocardial 
injections of stem cells, tagged with Technetium-
99m to evaluate the retention after 18 hours [4].
The echocardiogram, NT-proBNP and GGT do-
sage and walking test were performed, and then 
the cytokines network 3 months after the appli-
cation was compared. The response was definite, 
with an augment of LVEF ≥ 5% in 3 months. 
There was reduction of several cytokines and in-
flammatory markers levels, however, there was no 
significant difference in LVEF and in NT-proBNP. 
There was, however, a significant difference in 
GGT levels. Besides, the premature retention re-
sulted in a better clinical response, associated to 
a better LVEF [4].
A long-term experiment using the intracoro-
nary stem cell infusion in humans, from 2008 to 
2010, was performed. The patients were divided 
in two groups: group I, composed by patients with 
Functional Class I and II, and group II, composed 
by patients with Functional Class II and III. After 
this procedure, the patients were evaluated through 
echocardiographic exams and, accordingly the stu-
dy, those patients who had an augment of LVEF 
more than 5% were considered as performing a 
good therapeutic response [7].
The results have shown that approximately 77% 
of these patients had good therapeutic response, 
the most of them classified as group 1. Besides, the 
percentage of survival rate after 5 years was 69%, 
and this therapy was considered a secure treatment 
because it did not show adverse effects [7].
Experiments in humans and animals are being 
performed, in order to proven the efficacy of this 
treatment, as how to show possible malefic effects. 
One of these experiments, performed in rats through 
the use of doxirrubicin to induce dilated cardiom-
yopathy, was recently published. After this medica-
tion, the development of this pathology, through 
echocardiographic, electrocardiographic and usage 
of troponin I exams, was proven [2].
The animals were divided in two groups. The first 
group has received the infusion of enriched plaque 
plasma and the second one has received the infu-
sion of mesenchymal stem cells. The analysis has 
evidenced that the group treated with enriched 
plaque plasma has shown an augment of inflam-
matory factors due to an increase of MCP-1 expres-
sion [2].
Morschbacher et al., (2016) [2], highlighting 
Nagaya et al., (2005) [3], have observed that the 
previously describe experiment has shown benefic 
effects regarding the cardiac functioning, related to 
stem cell use, probably due to the development of 
mechanisms that increase the angiogenesis and an-
ti-apoptotic factors, like vascular endothelial growth 
factors and insulin-like growth factors. 
Kelkar et al., (2015) [6], emphasizing Gnecchi et 
al., (2008) [8], inform that this therapy promotes the 
progenitor endothelial cells migration to the target 
organ, and it is also involved with extracellular ma-
trix regulation, allowing an augment in perfusion 
and improvement in myocardial function. 
The research advancement in stem cell use was 
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innovated with a study performed in transgenic 
rats. Their cardiac function was altered, and the use 
of stem cells collected from human umbilical cord 
was tested. The results have shown great vantages 
compared to the use of stem cells collected from 
other human body structures, like bones [9].
The UCB-MSC (Umbilical Cord Blood Mesenchy-
mal Stem Cells) use has demonstrated a significant 
improvement of cardiac function after the intramyo-
cardial transplant in DCM rats, and this effect can 
be associated with reduction in cellular apoptosis, 
inflammation, hypertrophy and fibrosis of myocar-
dium. In a period of a month, there was improve-
ment of cardiac function with amelioration of ejec-
tion fraction, reduction of myocardial fibrosis and 
reduction of heart chambers size [9].
Gong et al., (2015) [9], citing Jin et al., (2013) 
[10], highlight that, compared to other stem cells, 
those cells collected from umbilical cord have great 
potential of cellular differentiation, they are easily 
collected and, finally, they have a low immuno-
genicity; thus, they can be extremely adequate to 
Table 1. Studies with Stem Cells in dilated cardiomyopathy.
Autor(s) Performed study
Period of 
study
Results Results
Gárzon et al., 
2016 [7]
Dilated idiopathic 
cardiomyopathy treated 
with intracoronary infusions 
of autologous cells of bone 
marrow 
2008 to 
2010
77% had an augment of ≥ 
5% in LVEF
The most common practices 
identified were homeopathy, Bach 
floral and oriental massage. 
Morschbacher 
et al., 2016 [2]
Treatment of dilated 
cardiomyopathy (DMC) in 
rabbits with mesenchymal 
stem cells (MSC), 
transformed in enriched 
plaque plasma 
The MSC transplant had 
diminished the DMC rate, 
improving the cardiac 
function, and also had 
demonstrated angiogenic 
factors production and 
reduction in apoptosis
Music, used as a facilitator of 
communication and movement, has 
been shown to attract the attention 
of the participants, placing it as a 
therapeutic option. It was shown able 
to facilitate the approach of people in 
the process of memory loss. 
Haddad et al., 
2015 [4]
Dilated long-term 
cardiomyopathy with 37 
patients, LVEF < 40% and 
NYHA III submitted to 
intramyocardial injections 
of stem cells, tagged with 
Tecnecium-99m to evaluate 
its retention after 18 hours
2011 to 
2012
Three months after SCT, 
there was a relative 
reduction of several 
cytokines and inflammatory 
markers
There is considerable evidence 
of efficacy for psychotherapeutic 
therapies in the treatment of coronary 
artery disease, headaches, insomnia, 
urinary incontinence, low back pain. 
Gong et al., 
2015 [9]
Use of stem cells 
collected from umbilical 
cord of humans to treat 
cardiomyopathy in 
transgenic rats
A month after the injection 
there was improvement 
of myocardial fibrosis, 
LVEF and diminishment of 
cardiac chambers. 
This research suggests that 
meditation improves memory and 
reduces Alzheimer's risk by improving 
sleep, decreasing depression, 
increasing well-being and decreasing 
inflammatory regulatory genes. It 
also improves a number of aspects 
of mental health, all of which are 
important for maintaining cognitive 
function, thus reducing the multiple 
risks of Alzheimer's.
Source: Author’s ownership.
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transplant, demonstrating greater possibility to be 
implemented in xenogenic tissues. 
Despite the promising studies with stem cells in 
dilated cardiomyopathy, more experiments are nec-
essary to better define this therapy as an effective 
treatment, better knowing its benefic and malefic 
effects. 
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